Previous 10 | Next 10 |
2023-12-27 09:10:12 ET More on Eli Lilly Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade) Eli Lilly: Long Path To A Trillion Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly Eli Lilly purcha...
Lilly Completes Acquisition of POINT Biopharma PR Newswire INDIANAPOLIS , Dec. 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmaceuti...
2023-12-27 00:01:00 ET Summary Market participants are increasingly factoring in the likelihood that the current series of rate hikes has concluded, with the Fed ‘dot plot’ of forward policy rate projections reinforcing that view and forecasting 75 bps of interest rate c...
2023-12-26 12:16:48 ET More on Fusion Pharmaceuticals Fusion Pharma shares jump following expanded actinium supply deal with BWXT Seeking Alpha’s Quant Rating on Fusion Pharmaceuticals Historical earnings data for Fusion Pharmaceuticals Financial infor...
2023-12-26 11:04:04 ET More on Utilities Select Sector SPDR ETF, Health Care Select Sector SPDR, etc.: XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector XLU: Please Don't Wait Until The Fed Cuts Before Buyi...
2023-12-26 10:26:50 ET Summary Coca-Cola is one of the leading beverage companies and has been a paragon of innovation in the soft drink industry for many decades. Currently, Coca-Cola's dividend yield is 3.1%, outperforming its major competitors in the consumer packaged goods (CP...
2023-12-26 07:43:47 ET More on POINT Biopharma Global Why POINT Biopharma Global Is At Least A Hold On Disappointing Readout POINT Biopharma Global: Why The Market Believes That A Second Bidder May Emerge Eli Lilly POINTs Toward Radiopharmaceutical Ambitions ...
2023-12-23 08:30:00 ET Summary Eli Lilly stock has underperformed the market since my previous caution, raising questions about whether significant optimism has been priced in. At an adjusted forward P/E of more than 50x, LLY investors looking to add at the current levels need to ...
2023-12-22 16:00:00 ET Biotech giant Eli Lilly (NYSE: LLY) has been firing on all cylinders this year. The company's popularity rose along with weight-loss medicine, an area in which it's one of the leaders. Its financial results have been solid, and its stock performance has crushe...
2023-12-22 07:15:00 ET Every major biopharma business is staking out territory to take advantage of the artificial intelligence (AI) gold rush. Amid a mishmash of strategies -- like forging partnerships with innovative software companies and biotechs, acquiring promising players, and develo...
News, Short Squeeze, Breakout and More Instantly...
2024-07-30 07:07:00 ET If your portfolio doesn't have exposure to the biopharma businesses pursuing the development of weight loss medicines, it might be time to consider changing that situation. With an influx of new drugs for sale, and many competitors looking to secure their share of the...
2024-07-30 05:48:00 ET Going into 2024, DexCom 's (NASDAQ: DXCM) shares were up a whopping 14 times over the last 10 years. The company's continuous glucose monitoring (CGM) devices enjoyed tremendous demand from individuals with diabetes. However, last week was the worst for De...
2024-07-29 15:13:21 ET Eli Lilly & Co (NYSE: LLY) has recently experienced a dramatic $123 billion decline in market value. This significant drop follows positive developments from competitors, notably Viking Therapeutics Inc and Roche Holding AG, who made announcements regarding th...